Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Growth Suppression of Cancer Spheroids With Mutated KRAS by Low-toxicity Compounds from Natural Products.

Anticancer research - 1 Aug 2021

Hashimoto Sayuri, Nagai Masayoshi, Nishi Kensuke, Ishikura Shuhei, Nakabayashi Kazuhiko, Yazaki Ryo, Ohshima Takashi, Suenaga Masahiko, Shirasawa Senji, Tsunoda Toshiyuki

Abstract excerpt

BACKGROUND/AIM: Among compounds from natural products selectively suppressing the growth of cancer spheroids, which have mutant (mt) KRAS, NP910 was selected and its derivatives explored. MATERIALS AND METHODS: The area of HKe3 spheroids expressing wild type (wt) KRAS (HKe3-wtKRAS) and mtKRAS (HKe3-mtKRAS) were measured in three-dimensional floating (3DF) cultures treated with 18 NP910 derivatives. The 50% cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biological Products

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Mice, Nude

Share to Proto-Oncogene Proteins p21(ras)

Share to Spheroids, Cellular

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 34281875
DOI: 10.21873/anticanres.15207

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Growth Suppression of Cancer Spheroids With Mutated KRAS by Low-toxicity Compounds from Natural Products.PMID 34281875Read ↗

A novel three-dimensional high-throughput screening approach identifies inducers of a mutant KRAS selective lethal phenotype.Semantic proximity Read ↗

Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cellsSemantic proximity Read ↗

KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer.Semantic proximity Read ↗

A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent CellsSemantic proximity Read ↗

Rasfonin, a novel 2-pyrone derivative, induces ras-mutated Panc-1 pancreatic tumor cell death in nude mice.Semantic proximity Read ↗

Shikonin Inhibits Cancer Through P21 Upregulation and Apoptosis InductionSemantic proximity Read ↗

Liver metastasis models of colon cancer for evaluation of drug efficacy using NOD/Shi-scid IL2Rγnull (NOG) miceSemantic proximity Read ↗

Combination effects of ellagic acid with erlotinib in a Ba/F3 cell line expressing EGFR H773_V774 insH mutation.Semantic proximity Read ↗

Synthetic Lethality of a Novel Small Molecule Against Mutant KRAS-Expressing Cancer Cells Involves AKT-Dependent ROS ProductionSemantic proximity Read ↗

Phytochemicals, withaferin A and carnosol, overcome pancreatic cancer stem cells as c-Met inhibitors.Semantic proximity Read ↗

KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.Semantic proximity Read ↗

TAN-1813, a novel Ras-farnesyltransferase inhibitor produced by Phoma sp. taxonomy, fermentation, isolation and biological activities in vitro and in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.